A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now. By Rebecca Robbins It’s easy to make a medical case for ...

LifeMD has a 12 month low of $3.99 and a 12 month high of $12.88. The company has a market capitalization of $241.25 million, a P/E ratio of -8.70 and a beta of 1.50.

With Lilly’s recent launch of additional doses of Zepbound vials and reduced pricing of existing vial doses, the integration will provide LifeMD’s eligible on-label patients with streamlined ...

Last week, it partnered with drugmaker Eli Lilly to offer the weight loss drug Zepbound directly to self-paying patients.

Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60%Adjusted EBITDA increased 78% to $9.0 millionTelehealth adjusted EBITDA increased 396% to $5.9 million ...

Tuesday saw KeyBanc Capital Markets reaffirm its Overweight rating on LifeMD Inc (NASDAQ:LFMD) stock, maintaining a price target of $7.50. The investment firm’s confidence in the telehealth provider ...

LifeMD produced tremendous results in the fourth ... authorization processes and overall infrastructure at LifeMD. For Zepbound, we've seen an 18 percentage point increase in the approval rate ...

LifeMD produced tremendous results in the fourth ... private insurance coverage for branded GLP-1 medications, especially for Zepbound. We believe this is partly due to private payer and employer ...

Last week, Eli Lilly, the maker of Zepbound, also cut prices for its starter dose to $349 per month. Larger doses will now cost $499 per month through the company’s self-pay program.

LifeMD had a great fourth quarter. We not only achieved record quarterly revenue and adjusted EBITDA but continued to accelerate growth across our core telehealth brands. We are especially pleased ...

LifeMD Inc (LFMD) reported a robust financial performance for the fourth quarter of 2024, significantly surpassing market expectations with an earnings per share (EPS) of $0.21 against a ...

Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60% Adjusted EBITDA increased 78% to $9.0 million Telehealth adjusted EBITDA increased 396% to $5.9 ...